In phase II clinical trials of cervical cancer, the objective response rate in patients with PD-L1–positive cervical cancer was 26.83%.[8–10] However, the PD-L1–positive rate varies according to the histological subtype of cervical cancer. This evidence concerns the gene CD274 and cervical carcinoma.